Breast and Ovarian Cancer Risk and Prevention
Research Studies
ExCel (MAP.3 Research Study): A Phase III Randomized Study of Exemestane versus Placebo
The goal of this study is to test whether Exemestane will lower the rate of breast cancer in healthy women who have an increased risk of the disease. Exemestane is approved by the Food and Drug Administration to treat breast cancer. It has been shown to reduce the chance that a breast cancer will come back. It also reduces the risk that a new breast cancer will develop in women who have already had a breast cancer. In the ExCel Trial, we are studying Exemestane to see whether it can prevent the development of breast cancer in healthy women.
Who is eligible?
You may be eligible to participate in the MAP3 study if:
- You are a woman over 50 years of age and you have not had a period in at least 12 months; or
- You are a woman under 50 years of age, you have not had a period in at least 12 months, and you have a hormone level (FSH) showing a postmenopausal range (this can include women who have had a hysterectomy or both ovaries removed);
- You are willing and able to complete quality of life questionnaires;
- You are able to provide informed consent to take part in this study; and you will be available for treatment and follow-up.
How long is the study?
Study treatment will last for five years.
What is involved?
If you are eligible to participate you will have a visit that will include a physical exam, routine blood tests, a bone mineral density scan (to look at bone strength) and a mammogram.
There will be two visits during the first year and annually thereafter for five years. At the visits, you will have a physical exam and complete a questionnaire about other aspects of your health, and any side effects. You will also have blood tests and a mammogram once a year.
Once you have finished the five-year study, we would like to check in with you once a year, but you will not have to come for visits unless you would like to.
How can I get more information about the ExCel trial?
For more information about this study please contact:
Hannah Green, MPH
hannah_green@dfci.harvard.edu
(617) 632-2359
